1. Ng SC, Shi HY, Hamidi N, et al.: Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 2769–78.
2. Manthey CF, Reher D, Huber S: Was ist gesichert in der Therapie chronisch-entzündlicher Darmerkrankungen. Internist 2021; 62: 1269–79.
3. Holstiege J, Klimke K, Akmatov MK, Kohring C, Dammertz L, Bätzing J: Bundesweite Verordnungstrends biologischer Arzneimittel bei häufigen Autoimmunerkrankungen, 2012 bis 2018. Versorgungsatlas 2021; Bericht Nr. 21/03.
4. Burisch J, Kiudelis G, Kupcinskas L, et al.: Natural disease course of Crohn‘s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 2019; 68: 423–33.
5. Burisch J, Katsanos KH, Christodoulou DK, et al.: Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort-an epi-IBD study. J Crohns Colitis 2019; 13: 198–208.